CONGRESS ABSTRACT

Introduction: Langerhans cell histiocytosis is a rare disease, more common in the pediatric age; the vinblastine–corticosteroid combination represents the first-line treatment. Cardiovascular effects of corticosteroids are generally mild; however, rare cases of obstructive hypertrophic cardiomyopathy have been described, mainly in the neonatal age. We report an exceptional case of…

Background: Cardiac involvement in hematologic malignancies is uncommon and often subclinical; it may present with pericardial effusion and myo-pericardial infiltration. Case presentation: A 41-year-old man with relapsed acute lymphoblastic leukemia (prior chemotherapy and two bone-marrow transplant attempts) was referred for hypotension and marked asthenia. He denied chest pain, palpitations,…

Introduction: Cardiotoxicity remains a major limitation in the use of anthracyclines and anti-HER2 agents, such as doxorubicin and trastuzumab, particularly when administered sequentially. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have demonstrated cardioprotective and anti-inflammatory properties beyond glycemic control. However, their potential role in mitigating chemotherapy-induced cardiac injury in…

Background Primary cardiac lymphoma is an extremely rare condition, accounting for less than 0.5% of extranodal lymphomas. It can present with a variety of symptoms, including pericardial effusion, heart failure, arrhythmias, or coronary artery compression. Accurate diagnosis requires a multimodal imaging approach—utilizing echocardiography, cardiac magnetic resonance (CMR), and PET-CT—complemented…

Background The clinical use of doxorubicin and trastuzumab in HER2-positive breast cancer is limited by significant cardiotoxicity. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), such as canagliflozin and dapagliflozin, have demonstrated cardiovascular protection in diabetes and heart failure, and emerging evidence suggests potential antineoplastic activity. Whether SGLT2is can simultaneously enhance antitumor…

Background: PIK3CA mutations occur in approximately 40% of hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancers and are associated with endocrine resistance. The combination of the PI3Kα inhibitor alpelisib and fulvestrant significantly improves progression-free survival (PFS) in this patient population, as demonstrated by the SOLAR-1 trial. However, treatment-induced hyperglycemia, observed in…